Challenges in Veterinary Vaccine Development

Thomas, Sunil; Abraham, Ann; Rodríguez-Mallón, Alina; Unajak, Sasimanas; Bannantine, John P.

doi:10.1007/978-1-0716-1888-2_1

Cited by 9 publications

(5 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expansion and intensification of pig, cattle, and poultry productions have resulted in significant changes to traditional husbandry practices leading to an environment conducive to increased emergence and spread of infectious diseases. These include several zoonotic viruses, including avian influenza, Japanese encephalitis, Nipah and coronaviruses, and others (McLean and Graham, 2022;Rathore et al, 2022;Thomas et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Odio¹,

Pérez²,

Batista-Duharte³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

Context: The new generation of immunoenhancers will have to offer solutions to each clinical and technological limitation that currently exists. This innovative context requires periodic technological surveillance by the veterinary biopharmaceutical industry to anticipate technological changes and predict future competitive advantages. Aims: To evaluate the current status, scientific trends, and technological projections in the use of veterinary immunological adjuvants for productive and companion species in the period 2015 and 2021. Methods: The bibliometric analysis included scientific articles on adjuvants in veterinary medicine published in English in 2015–2021 and indexed on the Scopus and Web of Science platforms. All relevant records retrieved between 2015 and 2022 were grouped using the EndNote bibliographic manager, while the analysis of the relational metric indicator was performed and viewed by VOSviewer®. Instead, data on the main commercial veterinary vaccine adjuvants in 2022 were collected from the official websites of 20 veterinary vaccine manufacturers with experience in the market. Results: The academy dedicated 68.2% of its production to disseminating articles with original experimental results with 73.6% being novel notifications about adjuvants of natural, microbial and nanotechnological origin. Industrial production mainly used monoadjuvation (86.9%), inorganic salts adjuvants (48.1%), particularly aluminum hydroxide (43.0%), and classical technology (89.2%) to produce their commercial formulations. Ruminants, swines, and poultry dominated both sectors, with ruminants being the main protagonist. Conclusions: The new scientific knowledge will not have a significant impact on the veterinary pharmaceutical industry in the short term and the hegemonic continuity of traditional adjuvants, in particular aluminum hydroxide, is expected.

show abstract

Section: Discussionmentioning

confidence: 99%

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Odio¹,

Pérez²,

Batista-Duharte³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

show abstract

“…Based on the likelihood of eliciting a T cell response, scientists can select some of the specific mutations as vaccine candidates. AI tools may enhance the accuracy of vaccine designs and overcome the challenges associated with the heterogeneity of tumors [442][443][444][445][446].…”

Section: Combining Artificial Intelligence and Cold Plasma Technology...mentioning

confidence: 99%

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Sheikhlary,

Lopez,

Moghimi

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Cancer remains one of the global leading causes of death and various vaccines have been developed over the years against it, including cell-based, nucleic acid-based, and viral-based cancer vaccines. Although many vaccines have been effective in in vivo and clinical studies and some have been FDA-approved, there are major limitations to overcome: (1) developing one universal vaccine for a specific cancer is difficult, as tumors with different antigens are different for different individuals, (2) the tumor antigens may be similar to the body’s own antigens, and (3) there is the possibility of cancer recurrence. Therefore, developing personalized cancer vaccines with the ability to distinguish between the tumor and the body’s antigens is indispensable. This paper provides a comprehensive review of different types of cancer vaccines and highlights important factors necessary for developing efficient cancer vaccines. Moreover, the application of other technologies in cancer therapy is discussed. Finally, several insights and conclusions are presented, such as the possibility of using cold plasma and cancer stem cells in developing future cancer vaccines, to tackle the major limitations in the cancer vaccine developmental process.

show abstract

“…The problem of enhancement in vectors and pathogens and novel diseases in birds has led to the urgent need for transmission control for emerging infectious diseases and the study of animal–human interaction in terms of Global Health. One of the major directions is the development of new vaccine technologies, especially for global poultry farming Thomas et al [ 22 ], summarizing these perspectives, describe the different challenges to be considered in the development of vaccines for animals. As humans and animals share a common environment and their health is closely connected, veterinary and medical services should actively cooperate to prevent risks to public health and work together in accordance with a One Health conception [ 23 ].…”

Section: Perspectives Of the “Avian Pathogens” Researchmentioning

confidence: 99%

Avian Pathogens: Editorial and the Perspectives of Research

Sharshov

2022

Microorganisms

View full text Add to dashboard Cite

In the last ten years, humanity has faced new challenges in the field of human and animal health, including emerging viral infections. The widespread occurrence of emerging and re-emerging pathogens (e.g., highly pathogenic avian influenza virus (HPAIV), the new COVID-2019 of zoonotic nature, coronaviruses that cause severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS)) presents a serious threat to humans. Avian pathogens cause devastating economic losses in poultry industries worldwide. Poultry is one of the main sources of protein in Asia. For instance, in China alone, with a population of more than 1.3 billion people, poultry meat consumption has increased to 19.6 kg/year per person (FAO). According to official estimates, this is over 25 million tons per year, or more than 12.7 billion birds. Therefore, poultry farming in Southeast Asia is considered one of the main “vessels” where avian pathogens can evolve. Wild bird migration makes the spread of these pathogens to other regions increasingly likely, as we have seen worldwide with the H5N8 influenza virus. In addition, avian pathogens can cause devastating epizootics among wild birds and threaten the planet’s bioresources. The importance of wild birds as potential vectors of disease has received recent renewed interest, especially in the frame of the global virome/microbiome concept. Understanding the spread of bacterial and viral pathogens in wild birds may serve as a useful model for examining the spread of other disease organisms, both among birds, and from birds to other taxa. This Special Issue aims to summarize recent advances and to attract new research articles that address existing pathogens in poultry and wild birds. It also aims to compare the epidemiological situation across avian pathogens or countries.

show abstract

Challenges in Veterinary Vaccine Development

Cited by 9 publications

References 104 publications

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Avian Pathogens: Editorial and the Perspectives of Research

Contact Info

Product

Resources

About